The Latest Breaking News on Pharma

Pfizer’s (PFE) co-developed COVID-19 vaccine booster for children, which recently got Emergency Use Authorization from the U.S. FDA, could boost its share price. The stock had witnessed significant attention during the pandemic and could still be worth owning. Let’s discuss this in detail….

NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing.

The California Cannabis Industry Association (CCIA), a trade group representing hundreds of companies participating in the United States’ largest regulated cannabis market, has released a white paper entitled “Pandora’s Box: The Dangers of a National, Unregulated, Hemp-Derived Intoxicating Cannabinoid Market.&

An FDA advisory panel voted 14-1 on Wednesday to recommend that the agency withdraw its approval of the drug Makena, saying the treatment does not appear to reduce the risk of preterm birth.

Amid the macroeconomic issues and rampant volatility in the market, investor sentiment toward biotech stocks is declining. Many companies in this space are planning layoffs to reduce expenses. Amid the grim backdrop, we think investors should drop fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Immunic (IMUX) from their…

There are fears of a "twindemic" of Covid and flu this winter

Health officials halve dose to eke out ‘extremely limited’ supply amid unprecedented rise in outbreaks

The Makena drug is the only one of its kind in the U.S.

A panel of federal advisers says a pregnancy drug intended to prevent premature births should be withdrawn because it doesn't work

The main Covid-19 booster offers good protection for at least three months.

Biotech firm’s data shows stronger immune response to Omicron than original vaccine three months after being given